Pharmaceuticals

WBDE

WBDE released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 374.21 M, actual EPS CNY 0.17

WBDE FY2026 Q1 Earnings Release Scheduled for April 30 After-Market BJT

WBDE to Release FY2025 Earnings on April 25 After-Market (BJT)

WBDE released FY2025 Q4 earnings on March 6 After-Market (BJT), actual revenue CNY 99.62 M, actual EPS CNY -0.1509

WBDE released FY2025 Annual Earnings on March 6 After-Market (BJT), Actual Revenue: CNY 1.117 B, Actual EPS: CNY -0.27

WBDE released FY2025 9 Months Earnings on October 29 During-Market (BJT), actual revenue CNY 1.018 B, actual EPS CNY 0.0225

WBDE released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 439.15 M, actual EPS CNY -0.0147

WBDE to Release FY2025 Q3 Earnings Report on October 30 During-Market BJT

WBDE released FY2025 Semi-Annual earnings on August 28 During-Market (BJT), actual revenue CNY 578.55 M, actual EPS CNY 0.02

WBDE released FY2025 Q2 earnings on August 28 During-Market (BJT), actual revenue CNY 263.44 M, actual EPS CNY -0.0023

WBDE to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Wanbangde Pharmaceutical Subsidiary Obtains Patent for Alzheimer's Treatment

Wanbangde Pharma Receives Approval for WP107 Myasthenia Gravis Clinical Trial

Wanbangde Pharmaceutical's Huperzine A Controlled-release Tablets Clinical Trial Approved

Wanbangde's Innovative Drugs Focus on Four Major Indication Areas

Wandong's Revenue and Profit Declined in Q1 2025

WBDE released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 315.11 M, actual EPS CNY 0.0249

Wanbangde Net Profit Up 12.66% in 2024

Wanbangde Subsidiary's Clinical Trial Application Approved by NMPA

WBDE FY2025 Q1 Earnings Release Scheduled for April 30 After-Market BJT

688302

600513

09992

603538

002082

Innovative drug concept stocks showed active performance, with JLPC touching the daily limit, Menovo hitting 5 daily limits in 6 days, and Kingchem, Hinova, SDKX, DEZHAN HEALTHCARE, and WBDE following suit. In morning trading, the military industry sector surged; Jianshe Industry hit 2 daily limits in 4 days, while North Long Dragon, GreatWall Military, Jieqiang Equipment, FIRMACO, and Guoke Group climbed

- On March 27, A-shares opened low but recovered slightly, with key indices reducing losses; various sectors like CRO and innovative pharmaceuticals showed strength, while memory and optical communication hardware adjusted.  
- The bond market saw a downturn, with government bond futures declining, and most domestic commodity futures also fell, particularly for indexes and certain metals.  
- Lithium battery material stocks remained strong, with significant production increases noted for energy storage cells, while innovative drug stocks and military sectors exhibited particular upward movements amidst geopolitical tensions affecting oil prices.

Wallstreetcn

Hinova

JLPC

POP MART

Menovo

SDKX

DEZHAN HEALTHCARE

North Long Dragon

Guoke Group

Jieqiang Equipment

Kingchem

FIRMACO

GreatWall Military

Shanghai Composite Nears Positive Territory, Pharmaceutical Stocks Surge, Computing Hardware Stocks Continue to Adjust, HSI Fluctuates Higher, New Consumption Concept Stocks Rebound, POP MART Rises 2%

The three major A-share indices rose by 0.3% to 0.9% in the half-day session. U.S. President Trump has extended the suspension of attacks on Iranian energy facilities until the 6th of next month, and the central parity rate of the RMB against the USD is reported at 6.89141. The People's Bank of China conducted a 146.2 billion yuan seven-day reverse repurchase operation today. In the first two months, profits of large-scale industrial enterprises in China increased by 15.2% year-on-year. Domestic bank stocks are slightly weak, with Industrial and Commercial Bank of China and China Construction Bank about to announce their earnings. Innovative drug concept stocks rose sharply, with WBDE and Menovo both hitting the daily limit

AASTOCKS

The three major A-share indices in Shanghai and Shenzhen rose by 0.3% to 0.9% in the first half of the day, with lithium mining stocks taking turns to rally and innovative drug concept stocks rising

On October 27th, WBDE announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., recently received a recognition letter from the U.S. Food and Drug Administration (FDA), granting orphan drug designation for WP203A for the treatment of pemphigus. Pemphigus is a severe autoimmune blistering disease characterized by widespread loose blisters and erosions on the skin and mucous membranes

Zhitong

WBDE: Subsidiary's product has received orphan drug designation in the United States

300086

600671

000623

The traditional Chinese medicine concept continues to rise, WBDE hits the limit up, Honz, TMSP, Zhenbao Island, JI LIN AO DONG and others follow suit

Honz

TMSP

JI LIN AO DONG

688331

09995

300436

002294

688428

09969

000661

The innovative drug concept has seen a surge, with CCHT rising over 8%, Xinghao Pharmaceutical and WBDE rising over 5%, and Tibet Pharmaceutical, REMEGEN, Salubris, Cosunter, and INNOCARE also following suit

RemeGen

REMEGEN

Cosunter

Salubris

InnoCare Pharma

INNOCARE

CCHT

Innovative drug concept experiences a surge, CCHT rises over 8%

WBDE announced that its controlling shareholder, WBDE Group, and its concerted parties have adjusted the share transfer price from RMB 6.88 per share to RMB 8.61 per share. The transferee, Wanlong Pharmaceutical, needs to pay a total price of RMB 517 million. Payment will be completed within one month after the share transfer registration, and the share transfer is subject to review by the Shenzhen Stock Exchange

WBDE: The share transfer price is adjusted to 8.61 yuan/share

WBDE announced that the Phase II/III clinical trial of its wholly-owned subsidiary WBDE Pharmaceutical Group Co., Ltd.'s donepezil controlled-release tablets for the treatment of mild to moderate Alzheimer's disease has completed the enrollment of the first subject. The drug utilizes a biphasic controlled-release technology aimed at improving the onset speed and safety of the medication, and supports once-daily dosing to enhance patient convenience and compliance. This trial will validate its clinical value and provide new options for Alzheimer's disease treatment

WBDE: The first subject has been enrolled in the Phase II/III clinical trial of Shishanjianjia controlled-release tablets

WBDE announced that in the first half of 2025, operating revenue was 579 million yuan, a year-on-year decrease of 23.15%. Net profit was 13.4635 million yuan, a year-on-year decrease of 64.29%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

WBDE: Net profit of 13.4635 million yuan in the first half of 2025, a year-on-year decrease of 64.29%

002900

000513

01513

600380

The innovative drug sector remains active, WBDE and MEDISAN hit the limit up in the afternoon, while LIVZON GROUP, Joincare, and Jinshi Yiyao followed suit

MEDISAN

LIVZON GROUP

LIVZON PHARMA

Joincare

The innovative drug sector remains active, WBDE and MEDISAN saw their stocks locked in the afternoon

WBDE's wholly-owned subsidiary has obtained an invention patent from the National Intellectual Property Administration, which involves compositions and their applications for the prevention and treatment of Alzheimer's disease and skin photoaging. The patent has developed a new drug compound composition that includes ginseng, ginkgo biloba leaves, and millepertuis, characterized by high safety, low dosage, and simple drug composition, providing a treatment solution superior to existing single-agent drugs

WBDE: Subsidiary obtains invention patents for the prevention and treatment of Alzheimer's disease and skin photoaging

WBDE(002082.SZ)